MIF contribution to progressive brain diseases.
AD
Astrocytoma
MIF
MS
Neurodegeneration
Neuroinflammation
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
03
07
2023
accepted:
12
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Progressive brain diseases create a huge social and economic burden on modern societies as a major cause of disability and death. Incidence of brain diseases has a significantly increasing trend and merits new therapeutic strategies. At the base of many progressive brain malfunctions is a process of unresolved, chronic inflammation. Macrophage migration inhibitory factor, MIF, is an inflammatory mediator that recently gained interest of neuro-researchers due to its varied effects on the CNS such as participation of nervous system development, neuroendocrine functions, and modulation of neuroinflammation. MIF appears to be a candidate as a new biomarker and target of novel therapeutics against numerous neurologic diseases ranging from cancer, autoimmune diseases, vascular diseases, neurodegenerative pathology to psychiatric disorders. In this review, we will focus on MIF's crucial role in neurological diseases such as multiple sclerosis (MS), Alzheimer's disease (AD) and glioblastoma (GBM).
Identifiants
pubmed: 38178143
doi: 10.1186/s12974-023-02993-6
pii: 10.1186/s12974-023-02993-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Subventions
Organisme : NIAMS NIH HHS
ID : AR078334
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153(3731):80–2.
pubmed: 5938421
doi: 10.1126/science.153.3731.80
David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A. 1966;56(1):72–7.
pubmed: 5229858
pmcid: 285677
doi: 10.1073/pnas.56.1.72
Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1989;86(19):7522–6.
pubmed: 2552447
pmcid: 298097
doi: 10.1073/pnas.86.19.7522
Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5):587–96.
pubmed: 17435771
doi: 10.1038/nm1567
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
pubmed: 25613900
doi: 10.1126/science.1260419
Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, Bäckström A, Danielsson F, Fagerberg L, Fall J, Gatto L, Gnann C, Hober S, Hjelmare M, Johansson F, Lee S, Lindskog C, Mulder J, Mulvey CM, Nilsson P, Oksvold P, Rockberg J, Schutten R, Schwenk JM, Sivertsson Å, Sjöstedt E, Skogs M, Stadler C, Sullivan DP, Tegel H, Winsnes C, Zhang C, Zwahlen M, Mardinoglu A, Pontén F, von Feilitzen K, Lilley KS, Uhlén M, Lundberg E. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321. https://doi.org/10.1126/science.aal3321 .
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507. https://doi.org/10.1126/science.aan2507 .
Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol. 2017;37(2–6):359–70.
pubmed: 29773026
doi: 10.1615/CritRevImmunol.v37.i2-6.90
Michell-Robinson MA, Touil H, Healy LM, Owen DR, Durafourt BA, Bar-Or A, et al. Roles of microglia in brain development, tissue maintenance and repair. Brain. 2015;138(Pt 5):1138–59.
pubmed: 25823474
pmcid: 5963417
doi: 10.1093/brain/awv066
Su Y, Wang Y, Zhou Y, Zhu Z, Zhang Q, Zhang X, et al. Macrophage migration inhibitory factor activates inflammatory responses of astrocytes through interaction with CD74 receptor. Oncotarget. 2017;8(2):2719–30.
pubmed: 27926507
doi: 10.18632/oncotarget.13739
Sumaiya K, Langford D, Natarajaseenivasan K, Shanmughapriya S. Macrophage migration inhibitory factor (MIF): a multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther. 2022;233: 108024.
pubmed: 34673115
doi: 10.1016/j.pharmthera.2021.108024
Song S, Xiao Z, Dekker FJ, Poelarends GJ, Melgert BN. Macrophage migration inhibitory factor family proteins are multitasking cytokines in tissue injury. Cell Mol Life Sci. 2022;79(2):105.
pubmed: 35091838
pmcid: 8799543
doi: 10.1007/s00018-021-04038-8
Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377(6544):68–71.
pubmed: 7659164
doi: 10.1038/377068a0
Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996;93(15):7849–54.
pubmed: 8755565
pmcid: 38837
doi: 10.1073/pnas.93.15.7849
Yao J, Leng L, Fu W, Li J, Bronner C, Bucala R. ICBP90 regulates MIF expression, glucocorticoid sensitivity, and apoptosis at the MIF immune susceptibility locus. Arthritis Rheumatol. 2021;73(10):1931–42.
pubmed: 33844457
doi: 10.1002/art.41753
Bernhagen J, Calandra T, Cerami A, Bucala R. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends Microbiol. 1994;2(6):198–201.
pubmed: 8087451
doi: 10.1016/0966-842X(94)90111-H
Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993;365(6448):756–9.
pubmed: 8413654
doi: 10.1038/365756a0
Lerch JK, Puga DA, Bloom O, Popovich PG. Glucocorticoids and macrophage migration inhibitory factor (MIF) are neuroendocrine modulators of inflammation and neuropathic pain after spinal cord injury. Semin Immunol. 2014;26(5):409–14.
pubmed: 24768088
doi: 10.1016/j.smim.2014.03.004
Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem. 1999;274(25):18100–6.
pubmed: 10364264
doi: 10.1074/jbc.274.25.18100
Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000;408(6809):211–6.
pubmed: 11089976
doi: 10.1038/35041591
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190(10):1375–82.
pubmed: 10562313
pmcid: 2195698
doi: 10.1084/jem.190.10.1375
Su H, Na N, Zhang X, Zhao Y. The biological function and significance of CD74 in immune diseases. Inflamm Res. 2017;66(3):209–16.
pubmed: 27752708
doi: 10.1007/s00011-016-0995-1
Sanchez-Nino MD, Sanz AB, Ruiz-Andres O, Poveda J, Izquierdo MC, Selgas R, et al. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. Cytokine Growth Factor Rev. 2013;24(1):23–40.
pubmed: 22959722
doi: 10.1016/j.cytogfr.2012.08.001
Kleemann R, Grell M, Mischke R, Zimmermann G, Bernhagen J. Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. J Interferon Cytokine Res. 2002;22(3):351–63.
pubmed: 12034043
doi: 10.1089/107999002753675785
Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197(11):1467–76.
pubmed: 12782713
pmcid: 2193907
doi: 10.1084/jem.20030286
Bucala R, Shachar I. The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis. Mini Rev Med Chem. 2014;14(14):1132–8.
pubmed: 25643611
doi: 10.2174/1389557515666150203144111
Gil-Yarom N, Radomir L, Sever L, Kramer MP, Lewinsky H, Bornstein C, et al. CD74 is a novel transcription regulator. Proc Natl Acad Sci U S A. 2017;114(3):562–7.
pubmed: 28031488
doi: 10.1073/pnas.1612195114
Kim BS, Tilstam PV, Hwang SS, Simons D, Schulte W, Leng L, et al. D-dopachrome tautomerase in adipose tissue inflammation and wound repair. J Cell Mol Med. 2017;21(1):35–45.
pubmed: 27605340
doi: 10.1111/jcmm.12936
Merk M, Mitchell RA, Endres S, Bucala R. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine. 2012;59(1):10–7.
pubmed: 22507380
pmcid: 3367028
doi: 10.1016/j.cyto.2012.03.014
Yao J, Leng L, Sauler M, Fu W, Zheng J, Zhang Y, et al. Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus. J Clin Invest. 2016;126(2):732–44.
pubmed: 26752645
pmcid: 4731159
doi: 10.1172/JCI81937
Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52(10):3020–9.
pubmed: 16200611
doi: 10.1002/art.21285
Mizue Y, Ghani S, Leng L, McDonald C, Kong P, Baugh J, et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A. 2005;102(40):14410–5.
pubmed: 16186482
pmcid: 1242335
doi: 10.1073/pnas.0507189102
Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000;10(5):359–66.
pubmed: 11100884
doi: 10.1006/scbi.2000.0328
O’Reilly C, Doroudian M, Mawhinney L, Donnelly SC. Targeting MIF in cancer: therapeutic strategies, current developments, and future opportunities. Med Res Rev. 2016;36(3):440–60.
pubmed: 26777977
doi: 10.1002/med.21385
Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol. 2013;33(Suppl 1):S72–8.
pubmed: 22968741
doi: 10.1007/s10875-012-9781-1
Leyton-Jaimes MF, Kahn J, Israelson A. Macrophage migration inhibitory factor: a multifaceted cytokine implicated in multiple neurological diseases. Exp Neurol. 2018;301(Pt B):83–91.
pubmed: 28679106
doi: 10.1016/j.expneurol.2017.06.021
Li S, Nie K, Zhang Q, Guo M, Qiu Y, Li Y, et al. Macrophage migration inhibitory factor mediates neuroprotective effects by regulating inflammation, apoptosis and autophagy in Parkinson’s disease. Neuroscience. 2019;416:50–62.
pubmed: 31170483
doi: 10.1016/j.neuroscience.2019.05.052
Israelson A, Ditsworth D, Sun S, Song S, Liang J, Hruska-Plochan M, et al. Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron. 2015;86(1):218–32.
pubmed: 25801706
pmcid: 4393372
doi: 10.1016/j.neuron.2015.02.034
Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180–8.
pubmed: 22466660
pmcid: 3314452
doi: 10.1172/JCI58649
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.
pubmed: 26250739
doi: 10.1038/nri3871
Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, Mirmosayyeb O, Shaygannejad V. Early predictors of conversion to secondary progressive multiple sclerosis. Mult Scler Relat Disord. 2021;54: 103115.
pubmed: 34216997
doi: 10.1016/j.msard.2021.103115
Liu YC, Tsai YH, Tang SC, Liou HC, Kang KH, Liou HH, et al. Cytokine MIF enhances blood-brain barrier permeability: impact for therapy in ischemic stroke. Sci Rep. 2018;8(1):743.
pubmed: 29335619
pmcid: 5768806
doi: 10.1038/s41598-017-16927-9
Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet’s disease. J Neurol Sci. 2000;179(S 1–2):127–31.
pubmed: 11054496
doi: 10.1016/S0022-510X(00)00397-X
Rinta S, Kuusisto H, Raunio M, Paalavuo R, Levula M, Lehtimaki T, et al. Apoptosis-related molecules in blood in multiple sclerosis. J Neuroimmunol. 2008;205(1–2):135–41.
pubmed: 18963025
doi: 10.1016/j.jneuroim.2008.09.002
Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J Neuroimmunol. 2011;234(1–2):141–7.
pubmed: 21397339
doi: 10.1016/j.jneuroim.2011.02.009
Cavalli E, Mazzon E, Basile MS, Mangano K, Di Marco R, Bramanti P, Nicoletti F, Fagone P, Petralia MC. Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T Cells from Clinically Isolated Syndrome Patients with Rapid Conversion to Clinical Defined Multiple Sclerosis. Medicina (Kaunas). 2019;55(10):667. https://doi.org/10.3390/medicina55100667 .
Rijvers L, Melief MJ, van der Vuurst de Vries RM, Stephant M, van Langelaar J, Wierenga-Wolf AF, et al. The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis. Eur J Immunol. 2018;48(11):1861–71.
pubmed: 30160778
pmcid: 6282801
doi: 10.1002/eji.201847623
Cox GM, Kithcart AP, Pitt D, Guan Z, Alexander J, Williams JL, et al. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. J Immunol. 2013;191(3):1043–54.
pubmed: 23797673
doi: 10.4049/jimmunol.1200485
Khaibullin T, Ivanova V, Martynova E, Cherepnev G, Khabirov F, Granatov E, et al. Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients. Front Immunol. 2017;8:531.
pubmed: 28572801
pmcid: 5435759
doi: 10.3389/fimmu.2017.00531
Hjaeresen S, Sejbaek T, Axelsson M, Mortensen SK, Vinslov-Jensen H, Pihl-Jensen G, et al. MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. J Neurol Sci. 2022;439: 120320.
pubmed: 35717879
doi: 10.1016/j.jns.2022.120320
Benedek G, Chaudhary P, Meza-Romero R, Calkins E, Kent G, Offner H, et al. Sex-dependent treatment of chronic EAE with partial MHC class II constructs. J Neuroinflamm. 2017;14(1):100.
doi: 10.1186/s12974-017-0873-y
Benedek G, Meza-Romero R, Jordan K, Zhang Y, Nguyen H, Kent G, et al. MIF and D-DT are potential disease severity modifiers in male MS subjects. Proc Natl Acad Sci U S A. 2017;114(40):E8421–9.
pubmed: 28923927
pmcid: 5635923
doi: 10.1073/pnas.1712288114
De la Cruz-Mosso U, Bucala R, Palafox-Sanchez CA, Parra-Rojas I, Padilla-Gutierrez JR, Pereira-Suarez AL, et al. Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-alpha in systemic lupus erythematosus. Hum Immunol. 2014;75(5):433–9.
pubmed: 24530749
pmcid: 4017948
doi: 10.1016/j.humimm.2014.02.014
Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernandez RE, Palafox-Sanchez CA, Padilla-Gutierrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013;61(3):759–65.
pubmed: 23402792
pmcid: 3683988
doi: 10.1016/j.cyto.2012.12.032
Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3(3):170–6.
pubmed: 12070782
doi: 10.1038/sj.gene.6363867
Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3942–51.
pubmed: 22127710
pmcid: 3228269
doi: 10.1002/art.30624
Morales-Zambrano R, Bautista-Herrera LA, De la Cruz-Mosso U, Villanueva-Quintero GD, Padilla-Gutierrez JR, Valle Y, et al. Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFalpha in psoriatic arthritis. Int J Clin Exp Med. 2014;7(9):2605–14.
pubmed: 25356116
pmcid: 4211766
Akcali A, Pehlivan S, Pehlivan M, Sever T, Neyal M. Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J Int Med Res. 2010;38(1):69–77.
pubmed: 20233515
doi: 10.1177/147323001003800108
Cevik B, Yigit S, Karakus N, Aksoy D, Ates O, Kurt S. Lack of association between MIF gene -173G>C polymorphism with multiple sclerosis. In Vivo. 2015;29(1):71–6.
pubmed: 25600533
Castaneda Moreno VA, Muñoz-Valle JF, Torres Carrillo N, Gonzalez Perez OP, Macias Islas MA, Ruiz Sandoval JL, Padilla De La Torre O, Trujillo Trujillo XA, Huerta Vieyra M. A case-control study on the association of MIF-794 CATT5-8 and-173 G> C polymorphisms and its serum levels and the clinical severity of multiple sclerosis in Mexican patients. Front Immunol. 2015. https://doi.org/10.3389/conf.fimmu.2015.05.00227 .
Castaneda-Moreno VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, Padilla-De la Torre O, Mireles-Ramirez MA, et al. MIF functional polymorphisms (-794 CATT(5–8) and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population. J Neuroimmunol. 2018;320:117–24.
pubmed: 29661540
doi: 10.1016/j.jneuroim.2018.04.006
Han Z, Qu J, Zhao J, Zou X. Genetic variant rs755622 regulates expression of the multiple sclerosis severity modifier D-dopachrome tautomerase in a sex-specific way. Biomed Res Int. 2018;2018:8285653.
pubmed: 30140701
pmcid: 6081589
doi: 10.1155/2018/8285653
Fagone P, Mazzon E, Cavalli E, Bramanti A, Petralia MC, Mangano K, et al. Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: in silico and in vivo evidences. J Neuroimmunol. 2018;322:46–56.
pubmed: 29935880
doi: 10.1016/j.jneuroim.2018.06.009
Powell ND, Papenfuss TL, McClain MA, Gienapp IE, Shawler TM, Satoskar AR, et al. Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol. 2005;175(9):5611–4.
pubmed: 16237048
doi: 10.4049/jimmunol.175.9.5611
Benedek G, Meza-Romero R, Andrew S, Leng L, Burrows GG, Bourdette D, et al. Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol. 2013;43(5):1309–21.
pubmed: 23576302
pmcid: 3788583
doi: 10.1002/eji.201243162
Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, et al. HLA-DRalpha1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. J Immunol. 2014;192(9):4164–73.
pubmed: 24683185
doi: 10.4049/jimmunol.1303118
Benedek G, Meza-Romero R, Jordan K, Keenlyside L, Offner H, Vandenbark AA. HLA-DRalpha1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. J Neuroinflamm. 2015;12:123.
doi: 10.1186/s12974-015-0342-4
Ji N, Kovalovsky A, Fingerle-Rowson G, Guentzel MN, Forsthuber TG. Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE. Neurol Neuroimmunol Neuroinflamm. 2015;2(5): e139.
pubmed: 26280015
pmcid: 4529283
doi: 10.1212/NXI.0000000000000139
Denkinger CM, Denkinger M, Kort JJ, Metz C, Forsthuber TG. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol. 2003;170(3):1274–82.
pubmed: 12538686
doi: 10.4049/jimmunol.170.3.1274
Kithcart AP, Cox GM, Sielecki T, Short A, Pruitt J, Papenfuss T, et al. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J. 2010;24(11):4459–66.
pubmed: 20624927
pmcid: 2974415
doi: 10.1096/fj.10-162347
Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A. 2010;107(25):11313–8.
pubmed: 20534506
pmcid: 2895110
doi: 10.1073/pnas.1002716107
Schwenkgrub J, Zaremba M, Mirowska-Guzel D, Kurkowska-Jastrzebska I. Ibudilast: a non-selective phosphodiesterase inhibitor in brain disorders. Postepy Hig Med Dosw (Online). 2017;71:137–48.
pubmed: 28258674
doi: 10.5604/01.3001.0010.3798
Oyama R, Yamamoto H, Titani K. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer’s disease brain by immunoprecipitation. Biochim Biophys Acta. 2000;1479(1–2):91–102.
pubmed: 11004532
doi: 10.1016/S0167-4838(00)00057-1
Lashuel HA, Aljabari B, Sigurdsson EM, Metz CN, Leng L, Callaway DJ, et al. Amyloid fibril formation by macrophage migration inhibitory factor. Biochem Biophys Res Commun. 2005;338(2):973–80.
pubmed: 16286092
doi: 10.1016/j.bbrc.2005.10.040
Bryan KJ, Zhu X, Harris PL, Perry G, Castellani RJ, Smith MA, et al. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer’s disease. Mol Neurodegener. 2008;3:13.
pubmed: 18786268
pmcid: 2565661
doi: 10.1186/1750-1326-3-13
Yoshiyama Y, Arai K, Oki T, Hattori T. Expression of invariant chain and pro-cathepsin L in Alzheimer’s brain. Neurosci Lett. 2000;290(2):125–8.
pubmed: 10936693
doi: 10.1016/S0304-3940(00)01326-4
Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. The role of macrophage migration inhibitory factor in Alzheimer’s disease. Mol Med. 2010;16(3–4):116–21.
pubmed: 20200619
pmcid: 2829616
doi: 10.2119/molmed.2009.00123
Carlred L, Michno W, Kaya I, Sjovall P, Syvanen S, Hanrieder J. Probing amyloid-beta pathology in transgenic Alzheimer’s disease (tgArcSwe) mice using MALDI imaging mass spectrometry. J Neurochem. 2016;138(3):469–78.
pubmed: 27115712
doi: 10.1111/jnc.13645
Li SQ, Yu Y, Han JZ, Wang D, Liu J, Qian F, et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer’s disease. J Neuroinflamm. 2015;12:177.
doi: 10.1186/s12974-015-0396-3
Liang CJ, Li JH, Zhang Z, Zhang JY, Liu SQ, Yang J. Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer’s disease. Acta Pharmacol Sin. 2018;39(9):1421–38.
pubmed: 29770796
pmcid: 6289349
doi: 10.1038/aps.2017.210
Al-Abed Y, VanPatten S. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem. 2011;3(1):45–63.
pubmed: 21428825
doi: 10.4155/fmc.10.281
Nasiri E, Sankowski R, Dietrich H, Oikonomidi A, Huerta PT, Popp J, et al. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer’s disease. Mol Med. 2020;26(1):34.
pubmed: 32303185
pmcid: 7164357
doi: 10.1186/s10020-020-00163-5
Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91(11):4766–70.
pubmed: 8197133
pmcid: 43869
doi: 10.1073/pnas.91.11.4766
Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2006;21(3):197–208.
pubmed: 16869341
doi: 10.1177/1533317506289277
Yu M, Zang D, Xu Y, Meng J, Qian S. Protective effect of ISO-1 against advanced glycation end product aggravation of PC12 cell injury induced by Abeta1-40. Mol Med Rep. 2019;20(3):2135–42.
pubmed: 31322215
pmcid: 6691208
Kassaar O, Pereira Morais M, Xu S, Adam EL, Chamberlain RC, Jenkins B, et al. Macrophage migration inhibitory factor is subjected to glucose modification and oxidation in Alzheimer’s Disease. Sci Rep. 2017;7:42874.
pubmed: 28230058
pmcid: 5322340
doi: 10.1038/srep42874
Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res. 2009;43(8):749–53.
pubmed: 19038405
doi: 10.1016/j.jpsychires.2008.10.006
Oikonomidi A, Tautvydaite D, Gholamrezaee MM, Henry H, Bacher M, Popp J. Macrophage migration inhibitory factor is associated with biomarkers of Alzheimer’s disease pathology and predicts cognitive decline in mild cognitive impairment and mild dementia. J Alzheimers Dis. 2017;60(1):273–81.
pubmed: 28826184
doi: 10.3233/JAD-170335
Zhang S, Zhao J, Zhang Y, Zhang Y, Cai F, Wang L, et al. Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease. Alzheimers Res Ther. 2019;11(1):54.
pubmed: 31174614
pmcid: 6555932
doi: 10.1186/s13195-019-0508-x
Bae SH, Yoo MR, Kim YY, Hong IK, Kim MH, Lee SH, et al. Brain-derived neurotrophic factor mediates macrophage migration inhibitory factor to protect neurons against oxygen-glucose deprivation. Neural Regen Res. 2020;15(8):1483–9.
pubmed: 31997812
pmcid: 7059593
doi: 10.4103/1673-5374.274340
Moon HY, Kim SH, Yang YR, Song P, Yu HS, Park HG, et al. Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc Natl Acad Sci U S A. 2012;109(32):13094–9.
pubmed: 22826223
pmcid: 3420190
doi: 10.1073/pnas.1205535109
Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–50.
pubmed: 28815663
doi: 10.1111/nan.12432
Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Caren H. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol. 2019;21(5):616–27.
pubmed: 30668814
pmcid: 6502500
doi: 10.1093/neuonc/noz011
Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789–94.
pubmed: 28346443
pmcid: 5558246
doi: 10.1038/ng.3823
Nobre CC, de Araujo JM, Fernandes TA, Cobucci RN, Lanza DC, Andrade VS, et al. Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer. Pathol Oncol Res. 2017;23(2):235–44.
pubmed: 27771887
doi: 10.1007/s12253-016-0138-6
Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer. 2009;115(10):2031–40.
pubmed: 19326434
doi: 10.1002/cncr.24245
Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 2007;26(3):281–5.
pubmed: 17376392
doi: 10.1016/j.immuni.2007.03.005
Kindt N, Journe F, Laurent G, Saussez S. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett. 2016;12(4):2247–53.
pubmed: 27698786
pmcid: 5038338
doi: 10.3892/ol.2016.4929
Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol. 2012;189(12):5533–40.
pubmed: 23125418
doi: 10.4049/jimmunol.1201161
Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160(12):5693–6.
pubmed: 9637476
doi: 10.4049/jimmunol.160.12.5693
Yan X, Orentas RJ, Johnson BD. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine. 2006;33(4):188–98.
pubmed: 16522371
pmcid: 2018658
doi: 10.1016/j.cyto.2006.01.006
Ghoochani A, Schwarz MA, Yakubov E, Engelhorn T, Doerfler A, Buchfelder M, et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene. 2016;35(48):6246–61.
pubmed: 27157615
doi: 10.1038/onc.2016.160
Alban TJ, Bayik D, Otvos B, Rabljenovic A, Leng L, Jia-Shiun L, et al. Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression. Front Immunol. 2020;11:1191.
pubmed: 32625208
pmcid: 7315581
doi: 10.3389/fimmu.2020.01191
Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, et al. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol. 2011;122(3):353–65.
pubmed: 21773885
doi: 10.1007/s00401-011-0858-3
Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L, et al. MIF receptor CD74 is restricted to microglia/macrophages, associated with a M1-polarized immune milieu and prolonged patient survival in gliomas. Brain Pathol. 2015;25(4):491–504.
pubmed: 25175718
doi: 10.1111/bpa.12194
Wang D, Luo L, Chen W, Chen LZ, Zeng WT, Li W, et al. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 2014;31(3):1199–204.
pubmed: 24366206
doi: 10.3892/or.2013.2946
Chang KP, Lin SJ, Liu SC, Yi JS, Chien KY, Chi LM, et al. Low-molecular-mass secretome profiling identifies HMGA2 and MIF as prognostic biomarkers for oral cavity squamous cell carcinoma. Sci Rep. 2015;5:11689.
pubmed: 26138061
pmcid: 4650660
doi: 10.1038/srep11689
Vera PL, Meyer-Siegler KL. Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis. BMC Res Notes. 2011;4:395.
pubmed: 22168770
pmcid: 3238298
doi: 10.1186/1756-0500-4-395
De Souza MB, Curioni OA, Kanda JL, De Carvalho MB. Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma. Oncol Lett. 2014;8(5):2267–75.
pubmed: 25289107
doi: 10.3892/ol.2014.2513
Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, et al. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol. 2003;162(1):11–7.
pubmed: 12507885
pmcid: 1851138
doi: 10.1016/S0002-9440(10)63793-5
Wang XB, Tian XY, Li Y, Li B, Li Z. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J Neurooncol. 2012;106(1):43–51.
pubmed: 21725855
doi: 10.1007/s11060-011-0640-3
Baron N, Deuster O, Noelker C, Stuer C, Strik H, Schaller C, et al. Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells. J Neurosci Res. 2011;89(5):711–7.
pubmed: 21360573
doi: 10.1002/jnr.22595
Baugh JA, Gantier M, Li L, Byrne A, Buckley A, Donnelly SC. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun. 2006;347(4):895–903.
pubmed: 16854377
doi: 10.1016/j.bbrc.2006.06.148
Guo X, Xu S, Gao X, Wang J, Xue H, Chen Z, et al. Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells. Oncotarget. 2017;8(46):80358–72.
pubmed: 29113309
pmcid: 5655204
doi: 10.18632/oncotarget.18673
Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN, et al. MIF expression in the rat brain: implications for neuronal function. Mol Med. 1998;4(4):217–30.
pubmed: 9606175
pmcid: 2230367
doi: 10.1007/BF03401919
Wei J, Gabrusiewicz K, Heimberger A. The controversial role of microglia in malignant gliomas. Clin Dev Immunol. 2013;2013: 285246.
pubmed: 23983766
pmcid: 3741958
doi: 10.1155/2013/285246
Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest. 2017;97(5):498–518.
pubmed: 28287634
doi: 10.1038/labinvest.2017.19
Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Can Res. 2017;77(9):2266–78.
doi: 10.1158/0008-5472.CAN-16-2310
Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells. 2016;34(8):2026–39.
pubmed: 27145382
doi: 10.1002/stem.2393
Kumar R, de Mooij T, Peterson TE, Kaptzan T, Johnson AJ, Daniels DJ, et al. Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. PLoS ONE. 2017;12(6): e0179012.
pubmed: 28666020
pmcid: 5493295
doi: 10.1371/journal.pone.0179012
Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, McGraw M, Huang P, Grabowski MM, Wathen CA, Ahluwalia MS, Radivoyevitch T, Kornblum HI, Kristensen BW, Vogelbaum MA, Lathia JD. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3(21):e122264. https://doi.org/10.1172/jci.insight.122264 .
Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009;1796(1):19–26.
pubmed: 19233249
pmcid: 2731828
Polajeva J, Bergstrom T, Edqvist PH, Lundequist A, Sjosten A, Nilsson G, et al. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner. Mol Oncol. 2014;8(1):50–8.
pubmed: 24091309
doi: 10.1016/j.molonc.2013.09.002
Ohta S, Kawakami Y, Okano H. MIF: functions in brain and glioblastoma. Oncotarget. 2017;8(29):46706–7.
pubmed: 28636550
pmcid: 5564516
doi: 10.18632/oncotarget.18489
Wang Z, Xue Y, Wang P, Zhu J, Ma J. MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor. Oncol Rep. 2016;35(5):2733–42.
pubmed: 26935642
doi: 10.3892/or.2016.4652
Fukaya R, Ohta S, Yaguchi T, Matsuzaki Y, Sugihara E, Okano H, et al. MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Res. 2016;76(9):2813–23.
pubmed: 26980763
doi: 10.1158/0008-5472.CAN-15-1011
Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal. 2019;57:76–88.
pubmed: 30682543
doi: 10.1016/j.cellsig.2019.01.006
Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25(4):595–606.
pubmed: 17045821
pmcid: 3707630
doi: 10.1016/j.immuni.2006.08.020
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.
pubmed: 17126425
doi: 10.1016/j.bbamcr.2006.10.001
Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405.
pubmed: 28431241
pmcid: 5546324
doi: 10.1016/j.cell.2017.04.001
Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26(35):5046–59.
pubmed: 17310986
doi: 10.1038/sj.onc.1210318
Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A. 2003;100(16):9354–9.
pubmed: 12878730
pmcid: 170922
doi: 10.1073/pnas.1533295100
Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, et al. Cell surface CD74-MIF interactions drive melanoma survival in response to interferon-gamma. J Invest Dermatol. 2015;135(11):2775–84.
pubmed: 26039541
pmcid: 4640965
doi: 10.1038/jid.2015.204
Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A. 2011;108(34):E577–85.
pubmed: 21817065
pmcid: 3161582
doi: 10.1073/pnas.1102941108
Kobold S, Merk M, Hofer L, Peters P, Bucala R, Endres S. The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model. Oncotarget. 2014;5(1):103–7.
pubmed: 24406307
doi: 10.18632/oncotarget.1560
Brock SE, Rendon BE, Yaddanapudi K, Mitchell RA. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J Biol Chem. 2012;287(45):37917–25.
pubmed: 22988252
pmcid: 3488063
doi: 10.1074/jbc.M112.378299
Coleman AM, Rendon BE, Zhao M, Qian MW, Bucala R, Xin D, et al. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol. 2008;181(4):2330–7.
pubmed: 18684922
doi: 10.4049/jimmunol.181.4.2330
Guo D, Guo J, Yao J, Jiang K, Hu J, Wang B, et al. D-dopachrome tautomerase is over-expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth. Int J Cancer. 2016;139(9):2056–67.
pubmed: 27434219
doi: 10.1002/ijc.30278
Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 2008;68(18):7253–7.
pubmed: 18794110
pmcid: 2726006
doi: 10.1158/0008-5472.CAN-07-6227
Lee SH, Kwon HJ, Park S, Kim CI, Ryu H, Kim SS, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP downregulates stemness phenotype and mesenchymal trans-differentiation after irradiation in glioblastoma multiforme. PLoS ONE. 2021;16(9): e0257375.
pubmed: 34516577
pmcid: 8437287
doi: 10.1371/journal.pone.0257375
Pasupuleti V, Du W, Gupta Y, Yeh IJ, Montano M, Magi-Galuzzi C, et al. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis. J Biol Chem. 2014;289(6):3713–23.
pubmed: 24356968
doi: 10.1074/jbc.M113.500694
Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, et al. Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget. 2018;9(25):17951–70.
pubmed: 29707160
pmcid: 5915168
doi: 10.18632/oncotarget.24885
Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37.
pubmed: 26892752
doi: 10.1016/j.jconrel.2016.02.026
Glaser T, Han I, Wu L, Zeng X. Targeted nanotechnology in glioblastoma multiforme. Front Pharmacol. 2017;8:166.
pubmed: 28408882
pmcid: 5374154
doi: 10.3389/fphar.2017.00166
Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, et al. Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer. 2009;9:464.
pubmed: 20038293
pmcid: 2810303
doi: 10.1186/1471-2407-9-464
Piette C, Deprez M, Roger T, Noel A, Foidart JM, Munaut C. The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem. 2009;284(47):32483–92.
pubmed: 19759012
pmcid: 2781663
doi: 10.1074/jbc.M109.014589
Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, et al. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol. 2010;100(2):177–86.
pubmed: 20443131
pmcid: 3233976
doi: 10.1007/s11060-010-0186-9
Ha W, Sevim-Nalkiran H, Zaman AM, Matsuda K, Khasraw M, Nowak AK, et al. Ibudilast sensitizes glioblastoma to temozolomide by targeting macrophage migration inhibitory factor (MIF). Sci Rep. 2019;9(1):2905.
pubmed: 30814573
pmcid: 6393433
doi: 10.1038/s41598-019-39427-4
Berkova Z, Tao RH, Samaniego F. Milatuzumab—a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 2010;19(1):141–9.
pubmed: 19968579
doi: 10.1517/13543780903463854
Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008;283(5):2784–92.
pubmed: 18056708
doi: 10.1074/jbc.M703265200
Wallace DJ, Figueras F, Wegener WA, Goldenberg DM. Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). Ann Rheum Dis. 2021;80(7):954–5.
pubmed: 33619162
doi: 10.1136/annrheumdis-2020-219803
Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, et al. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020;86(9):1836–48.
pubmed: 32207164
pmcid: 7444762
doi: 10.1111/bcp.14289
Pantouris G, Syed MA, Fan C, Rajasekaran D, Cho TY, Rosenberg EM Jr, et al. An analysis of MIF structural features that control functional activation of CD74. Chem Biol. 2015;22(9):1197–205.
pubmed: 26364929
pmcid: 4575896
doi: 10.1016/j.chembiol.2015.08.006
Fingerle-Rowson G, Kaleswarapu DR, Schlander C, Kabgani N, Brocks T, Reinart N, et al. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol. 2009;29(7):1922–32.
pubmed: 19188446
pmcid: 2655604
doi: 10.1128/MCB.01907-08
Orita M, Yamamoto S, Katayama N, Fujita S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr Pharm Des. 2002;8(14):1297–317.
pubmed: 12052220
doi: 10.2174/1381612023394674
Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002;277(28):24976–82.
pubmed: 11997397
doi: 10.1074/jbc.M203220200
Cournia Z, Leng L, Gandavadi S, Du X, Bucala R, Jorgensen WL. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009;52(2):416–24.
pubmed: 19090668
pmcid: 2680181
doi: 10.1021/jm801100v
Hare AA, Leng L, Gandavadi S, Du X, Cournia Z, Bucala R, et al. Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010;20(19):5811–4.
pubmed: 20728358
pmcid: 2939296
doi: 10.1016/j.bmcl.2010.07.129
Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, et al. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol. 2011;186(1):527–38.
pubmed: 21106847
doi: 10.4049/jimmunol.1001767
Nakamura A, Zeng F, Nakamura S, Reid KT, Gracey E, Lim M, et al. Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. Sci Transl Med. 2021;13(616):eabg1210.
pubmed: 34669443
doi: 10.1126/scitranslmed.abg1210
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846–55.
pubmed: 30157388
pmcid: 6172944
doi: 10.1056/NEJMoa1803583
Tilstam PV, Pantouris G, Corman M, Andreoli M, Mahboubi K, Davis G, et al. A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity. J Biol Chem. 2019;294(49):18522–31.
pubmed: 31578280
pmcid: 6901300
doi: 10.1074/jbc.RA119.009860
Xiao Z, Osipyan A, Song S, Chen D, Schut RA, van Merkerk R, et al. Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione derivative inhibits d-dopachrome tautomerase activity and suppresses the proliferation of non-small cell lung cancer cells. J Med Chem. 2022;65(3):2059–77.
pubmed: 35041425
pmcid: 8842245
doi: 10.1021/acs.jmedchem.1c01598
Rajasekaran D, Zierow S, Syed M, Bucala R, Bhandari V, Lolis EJ. Targeting distinct tautomerase sites of D-DT and MIF with a single molecule for inhibition of neutrophil lung recruitment. FASEB J. 2014;28(11):4961–71.
pubmed: 25016026
pmcid: 4200328
doi: 10.1096/fj.14-256636
Meza-Romero R, Benedek G, Jordan K, Leng L, Pantouris G, Lolis E, et al. Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74. Cytokine. 2016;88:62–70.
pubmed: 27573366
pmcid: 5067215
doi: 10.1016/j.cyto.2016.08.024
Burrows GG, Chang JW, Bachinger HP, Bourdette DN, Offner H, Vandenbark AA. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 1999;12(9):771–8.
pubmed: 10506287
doi: 10.1093/protein/12.9.771
Burrows GG. Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands. Curr Drug Targets Inflamm Allergy. 2005;4(2):185–93.
pubmed: 15853741
pmcid: 3457802
doi: 10.2174/1568010053586363
Offner H, Sinha S, Wang C, Burrows GG, Vandenbark AA. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev Neurosci. 2008;19(4–5):327–39.
pubmed: 19145988
pmcid: 2629410
Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK, et al. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. J Autoimmun. 2013;40:96–110.
pubmed: 23026773
doi: 10.1016/j.jaut.2012.08.004
Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35–55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol. 2003;171(1):127–33.
pubmed: 12816990
doi: 10.4049/jimmunol.171.1.127
Yadav V, Bourdette DN, Bowen JD, Lynch SG, Mattson D, Preiningerova J, et al. Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: a double-blind, placebo-controlled, phase 1, dose-escalation study. Autoimmune Dis. 2012;2012: 954739.
pubmed: 22548151
pmcid: 3328144
Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA. RTL therapy for multiple sclerosis: a phase I clinical study. J Neuroimmunol. 2011;231(1–2):7–14.
pubmed: 20965577
doi: 10.1016/j.jneuroim.2010.09.013
Vandenbark AA, Meza-Romero R, Benedek G, Offner H. A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury. J Neuroinflamm. 2019;16(1):14.
doi: 10.1186/s12974-018-1393-0
Vandenbark AA, Meza-Romero R, Wiedrick J, Gerstner G, Headrick A, Kent G, et al. Brief report: enhanced DRalpha1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice. Cell Immunol. 2021;370: 104439.
pubmed: 34607646
pmcid: 8920317
doi: 10.1016/j.cellimm.2021.104439
Vandenbark AA, Meza-Romero R, Wiedrick J, Gerstner G, Seifert H, Kent G, et al. “Near Cure” treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct. Cell Immunol. 2022;378: 104561.
pubmed: 35738135
pmcid: 9714992
doi: 10.1016/j.cellimm.2022.104561
Meza-Romero R, Benedek G, Gerstner G, Kent G, Nguyen H, Offner H, et al. Increased CD74 binding and EAE treatment efficacy of a modified DRalpha1 molecular construct. Metab Brain Dis. 2019;34(1):153–64.
pubmed: 30353480
doi: 10.1007/s11011-018-0331-2